Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
The DOI matches its Crossref record; 45 of the 48 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog developed for type 2 diabetes. Long-term liraglutide exposure in rodents was associated with thyroid C-cell hyperplasia and tumors. Here, we report data supporting a GLP-1 receptor-mediated mechanism for these changes in rodents. The GLP-1 receptor was localized to rodent C-cells. GLP-1 receptor agonists stimulated calcitonin release, up-regulation of calcitonin gene expression, and subsequently C-cell hyperplasia in rats and, to a lesser extent, in mice. In contrast, humans and/or cynomolgus monkeys had low GLP-1 receptor expression in thyroid C-cells, and GLP-1 receptor agonists did not activate adenylate cyclase or generate calcitonin release in primates. Moreover, 20 months of liraglutide treatment (at >60 times human exposure levels) did not lead to C-cell hyperplasia in monkeys. Mean calcitonin levels in patients exposed to liraglutide for 2 yr remained at the lower end of the normal range, and there was no difference in the proportion of patients with calcitonin levels increasing above the clinically relevant cutoff level of 20 pg/ml. Our findings delineate important species-specific differences in GLP-1 receptor expression and action in the thyroid. Nevertheless, the long-term consequences of sustained GLP-1 receptor activation in the human thyroid remain unknown and merit further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1792]
In the citing paper
“Among rodents receiving liraglutide, higher rates of thyroid C-cell tumors and hyperplasia have been observed than were observed among control animals.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [27]
In the citing paper
“Treatment with liraglutide or exenatide has been associated with thyroid C‐cell proliferation and the formation of thyroid C‐cell tumours in rodents, 104 although the relevance to humans is uncertain.”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [104]
In the citing paper
“Pharmacological studies in rodents support an association between the use of GLP-1 RAs and the development of medullary thyroid cancer (MTC) resulting in a black box warning for these agents in patients at risk for this condition.”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [23]
In the citing paper
“The association between GLP-1 RAs and MTC in humans has not been proven, and studies have shown interspecies differences regarding the density of GLP-1 receptors and responses to GLP-1 RA activation in the thyroid, limiting the predictive value of nonhuman preclinical studies on humans.23,24,46”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [23]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
International Union of Pharmacology. XXXV. The Glucagon Receptor Family
Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 506
Self-citationGLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477
C-Cell Hyperplasia Preceding Medullary Thyroid Carcinoma
Wolfe, H. J., Melvin, K. E. W., Cervi-Skinner, S. J., AL Saadi, A. A., Juliar, J. F., Jackson, C. E., & Tashjian, A. H. (1973) · New England Journal of Medicine · doi:10.1056/nejm197308302890901 · Cited by 449
Pyke, C., Rømer, J., Kallunki, P., Lund, L. R., Ralfkiaer, E. M., Danø, K., & Tryggvason, K. (1994) · PubMed Central · Cited by 272
Möhr, U., Dungworth, D. L., & Capen, C. C. (1993) · Medical Entomology and Zoology · Cited by 252
Matveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., & Butler, P. C. (2009) · Diabetes · doi:10.2337/db09-0058 · Cited by 242
GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells
Egan, J. M., Bulotta, A., Hui, H., & Perfetti, R. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.357 · Cited by 209
Larsen, J., Hylleberg, B., Ng, K., & Damsbo, P. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1416 · Cited by 171
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro
Bregenholt, S., Møldrup, A., Blume, N., Karlsen, A. E., Friedrichsen, B. N., Tornhave, D., Knudsen, L. B., & Petersen, J. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.013 · Cited by 170
Self-citationThe Effects of Xenobiotics on the Structure and Function of Thyroid Follicular and C-Cells
Capen, C. C., & Martin, S. L. (1989) · Toxicologic Pathology · doi:10.1177/019262338901700205 · Cited by 137
Freichel, M., Zink-Lorenz, A., Holloschi, A., et al. (1996) · Endocrinology · doi:10.1210/endo.137.9.8756555 · Cited by 135
Karges, W., Dralle, H., Raue, F., Mann, K., Reiners, C., Grußendorf, M., Hüfner, M., Niederle, B., & Brabant, G. E. (2004) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2004-815727 · Cited by 115
The Role of GLP-1 in the Life and Death of Pancreatic Beta Cells
Perfetti, R., & Hui, H. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826167 · Cited by 86
Machens, A., Hoffmann, F., Sekulla, C., & Dralle, H. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0136 · Cited by 82
Point Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line
Carlomagno, F., Salvatore, D., Santoro, M., Defranciscis, V., Quadro, L., Panariello, L., Colantuoni, V., & Fusco, A. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1287 · Cited by 78
Dual Inhibition of RET and FGFR4 Restrains Medullary Thyroid Cancer Cell Growth
Ezzat, S., Huang, P., Dackiw, A. P. B., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1336.11.3 · Cited by 76
Is Calcitonin an Important Physiological Substance?
Hirsch, P. F., & Baruch, H. (2003) · Endocrine · doi:10.1385/endo:21:3:201 · Cited by 73
Lamari, Y., Boissard, C., Moukhtar, M. S., Jullienne, A., Rosselin, G., & Garel, J.-M. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00895-2 · Cited by 73
Role of MEN2A-Derived RET in Maintenance and Proliferation of Medullary Thyroid Carcinoma
Drosten, M., Hilken, G., Bockmann, M. R., Rödicker, F., Mise, N., Cranston, A. N., Dahmen, U., Ponder, B. A. J., & Pützer, B. M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh226 · Cited by 71
Crespel, A., De Boisvilliers, F., Gros, L., & Kervran, A. (1996) · Endocrinology · doi:10.1210/endo.137.9.8756532 · Cited by 67
O’Toole, K., Fenoglio‐Preiser, C. M., & Pushparaj, N. (1985) · Human Pathology · doi:10.1016/s0046-8177(85)80276-8 · Cited by 62
Vitale, G., Ciccarelli, A., Caraglia, M., Galderisi, M., Rossi, R., Prete, S. D., Abbruzzese, A., & Lupoli, G. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.9.1505 · Cited by 47
C‐cell hyperplasia in secondary hyperparathyroidism
Tomita, T., & Millard, D. M. (1992) · Histopathology · doi:10.1111/j.1365-2559.1992.tb00433.x · Cited by 47
Bock, T. G., Pakkenberg, B., & Buschard, K. (2003) · Apmis · doi:10.1111/j.1600-0463.2003.apm1111207.x · Cited by 46
Erdoğan, M. F., Güllü, S., Başkal, N., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3797 · Cited by 41
Gallel, P., Pallarés, J., Dolcet, X., et al. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.11.015 · Cited by 33
Role of calcitonin in the rapid minute‐to‐minute regulation of plasma Ca2+ homeostasis in the rat
Wang, W., Lewin, E., & Ølgaard, K. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.01054.x · Cited by 28
Martín‐Lacave, I., Conde, E., Montero, C., et al. (1992) · Cell and Tissue Research · doi:10.1007/bf00381881 · Cited by 27
Vertongen, P., CICCARELLI, E., Woussen-Colle, M. C., NEEF, P. D., Robberecht, P., & Cauvin, A. J. (1994) · Endocrinology · doi:10.1210/endo.135.4.7925114 · Cited by 25
Correlation between gender and spontaneous C-cell tumors in the thyroid gland of the Wistar rat
Martín‐Lacave, I., Bernabé, R., Sampedro, C., Conde, E., Fernández-Santos, J. M., Martín, M. V. S., Beato, A., & Galera-Davidson, H. (1999) · Cell and Tissue Research · doi:10.1007/s004410051371 · Cited by 19
Experimental induction of C cell tumours in thyroid by increased dietary content of vitamin D3
Thurston, V., & Williams, E. D. (1982) · European Journal of Endocrinology · doi:10.1530/acta.0.1000041 · Cited by 18
Radioimmunoassay of calcitonin in the plasma of rhesus monkey and man.
HARGIS, G. K., Reynolds, W. A., WILLIAMS, G. A., et al. (1978) · Clinical Chemistry · doi:10.1093/clinchem/24.4.595 · Cited by 14
Mechanism of Dietary Modulation of Calcitonin Levels in Fischer Rats
Kalu, D. N., Herbert, D. C., Hardin, R. R., et al. (1988) · Journal of Gerontology · doi:10.1093/geronj/43.5.b125 · Cited by 14
Omeprazole: short- and long-term safety.
Yeomans, N. D. (1994) · PubMed · Cited by 11
β-Cell Replication by Loosening the Brakes of Glucagon-Like Peptide-1 Receptor Signaling
Schuit, F. C., & Drucker, D. J. (2008) · Diabetes · doi:10.2337/db07-1578 · Cited by 10
Self-citationSecretion of calcitonin from the thyroid gland increases in aged rats
Kurosawa, M., Sato, A., Shiraki, M., & Takahashi, Y. (1988) · Archives of Gerontology and Geriatrics · doi:10.1016/0167-4943(88)90006-4 · Cited by 8
Swarup, K., Das, S., & Das, V. K. (1979) · PubMed · Cited by 6
de Lima, M. A., Tiveron, F. S., dos Santos, V. M., Lima, L. M. B., Silva, G. P., & Borges, M. F. (2003) · Revista do Hospital das Clínicas · doi:10.1590/s0041-87812003000600004 · Cited by 3
Research works printed but not linked: 4
- Leong, 1981, A new cell line for studies on human thyroid medullary carcinoma., Rev Hosp Clin Fac Med Sao Paulo, 58, 310
- Hiles, 2004, Exenatide does not cause pancreatic islet cell proliferative lesions in rats and mice following 2-year exposure., Diabetologia, 47, A208
- Food and Drug Administration 2005 Byetta (exenatide), pharmacology review 2005.
- Food and Drug Administration 2002 Forteo (teriparatide), medical review 2002: Part 3.
Cited by
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“In contrast, the density of GLP-1Rs on monkey and human thyroid cells is extremely low, and sustained GLP-1R agonism does not cause calcitonin secretion, C cell hyperplasia, or MTC in non-human primates (Bjerre Knudsen et al., 2010; Vahle et al., 2015).”
BackgroundSelf-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“thyroid [855,856], and involvement of calcitonin in GLP-1-mediated osteoclast activation has been suspected [854].”
BackgroundSelf-citationGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“Nevertheless, thyroid C cells express GLP-1 receptors [107], and subjects at risk of (rare) medullary thyroid cancer (e.”
Background
Metadata
- Authors
- Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., Jacobsen, S. D., Moses, A. C., Mølck, A.-M., Nielsen, H. S., Nowak, J., Solberg, H., Thi, T. D. L., & Zdravkovic, M.
- Affiliations
- Novo Nordisk A/S (L.B.K., L.W.M., S.A., K.A., A.S.d.B., C.G., F.L.E., A.C.H., H.J., S.D.J., A.C.M., A.M.M., H.S.N., J.N., H.S., T.D.L.T., M.Z.), DK-2760 Maaloev, Denmark
- Novo Nordisk (Denmark) (DK)
- Mount Sinai Hospital (CA)
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2010-03-04
- Volume
- 151
- Issue
- 4
- Pages
- 1473-1486
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2004409542
- Cited by
- 672
- References
- 48
- Citations by year
- 2026: 55 · 2025: 83 · 2024: 58 · 2023: 29 · 2022: 26 · 2021: 18 · 2020: 17 · 2019: 28 · 2018: 26 · 2017: 38 · 2016: 25 · 2015: 39 · 2014: 42 · 2013: 56 · 2012: 48
- FWCI
- 45.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amylin Pharmaceuticals
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- GLP-1 receptor agonists, liraglutide, thyroid C cells, C-cell hyperplasia, species differences, drug safety, type 2 diabetes, adenylate cyclase, thyroid cancer risk
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cyclic AMP, Animals, Calcitonin, Cell Line, Cells, Cultured, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, Humans, Immunohistochemistry, Macaca fascicularis, Obesity, Radioimmunoassay, RNA, Messenger, Species Specificity, Thyroid Gland, Blotting, Western, Gene Expression, Rats, Sprague-Dawley, In Situ Hybridization, Receptors, Glucagon, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Cell Proliferation, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.